5-ht7 receptor antagonists

ABSTRACT

The invention relates to compounds having pharmacological activity towards the 5-receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.

This application is a divisional application of U.S. patent applicationSer. No. 11/813,069, filed Oct. 10, 2007 (now allowed); which is anational phase application under 35 U.S.C. §371 of InternationalApplication No. PCT/EP2005/014044, filed Dec. 27, 2005, entitled “5-HT7Receptor Antagonists”; which claims the benefit of European PatentApplication No. 04380280.0, filed Dec. 28, 2004 and U.S. patentapplication Ser. No. 11/048,991, filed Feb. 2, 2005 (now abandoned), allof which are incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to compounds having pharmacologicalactivity towards the 5-HT7 receptor, and more particularly to some2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamidecompounds, to processes of preparation of such compounds, topharmaceutical compositions comprising them, and to their use intherapy, in particular for the treatment and/or prophylaxis of a diseasein which 5-HT7 is involved, such as CNS disorders.

BACKGROUND OF THE INVENTION

The search for new therapeutic agents has been greatly aided in recentyears by better understanding of the structure of proteins and otherbiomolecules associated with target diseases. One important class ofproteins that has been the subject of extensive study is the family of5-hydroxytryptamine (serotonin, 5-HT) receptors. The 5-HT7 receptordiscovered in 1993 belongs to this family and has attracted greatinterest as a valuable new drug target (Terrón, J. A. Idrugs, 1998, vol.1, no. 3, pages 302-310: “The SHT₇ receptor: A target for noveltherapeutic avenues?”).

5-HT7 receptors have been cloned from rat, mouse, guinea pig and humancDNA and exhibit a high degree of interspecies homology (approx. 95%),but it is unique in that it has a low sequence homology with other 5-HT₇receptors (less than 40%). Its expression pattern, in particularstructures of the central nervous system (CNS) (highest in hypothalamus(in particular suprachiasmatic nuclei) and thalamus) and otherperipheral tissues (spleen, kidney, intestinal, heart and coronaryartery), implicates the 5-HT₇ receptor in a variety of functions andpathologies. This idea is reinforced by the fact that severaltherapeutic agents, such as tricyclic antidepressants, typical andatypical antipsychotics and some 5-HT₂ receptor antagonists, displaymoderate to high affinity for both recombinant and functional 5-HT₇receptors.

Functionally, the 5-HT₇ receptor has been implicated in regulation ofcircadian rhythms in mammals (Lovenberg, T. W. et al. Neuron, 1993,11:449-458 “A novel adenylyl cyclase-activating serotonin receptor(5-HT₇) implicated in the regulation of circadian rhythms”). It is knownthat disruption of circadian rhythms is related to a number of CNSdisorders including depression, seasonal affective disorder, sleepdisorders, shift worker syndrome and jet lag among others.

Distribution and early pharmacological data also suggest that the 5-HT₇receptor is involved in the vasodilatation of blood vessels. This hasbeen demonstrated in vivo (Terrón, J. A., Br J Pharmacol, 1997,121:563-571 “Role of 5-HT₇ receptors in the long lasting hypotensiveresponse induced by 5-hydroxytryptamine in the rat”). Thus selective5-HT₇ receptor agonists have a potential as novel hypertensive agents.

The 5-HT₇ receptor has also been related with the pathophysiology ofmigraine through smooth muscle relaxation of cerebral vessels(Schoeffter, P. et al., 1996, Br J Pharmacol, 117:993-994; Terrón, J.A., 2002, Eur. J. Pharmacol., 439:1-11 “Is the 5-HT₇ receptor involvedin the pathogenesis and prophylactic treatment of migraine?”). In asimilar manner, involvement of 5-HT₇ in intestinal and colon tissuesmooth muscle relaxation makes this receptor a target for the treatmentof irritable bowel syndrome (De Ponti, F. et al., 2001, Drugs,61:317-332 “Irritable bowel syndrome. New agents targeting serotoninreceptor subtypes”). Recently, it has also been related to urinaryincontinence (British J. of Pharmacology, September 2003, 140(1) 53-60:“Evidence for the involvement of central 5HT-7 receptors in themicurition reflex in anaesthetized female rats”).

In view of the potential therapeutic applications of agonists orantagonists of the 5HT₇ receptor, a great effort has been directed tofind selective ligands. Despite intense research efforts in this area,very few compounds with selective 5-HT₇ antagonist activity have beenreported (Wesolowska, A., Polish J. Pharmacol., 2002, 54: 327-341, “Inthe search for selective ligands of 5-HT₅, 5-HT₆ and 5-HT₇ serotoninreceptors”).

WO 97/48681 discloses sulfonamide derivatives, which are 5-HT₇ receptorantagonists, for the treatment of CNS disorders. The sulphur atom islinked to an aromatic group and to a N-containing heterocyclic group,optionally containing a further heteroatom selected from oxygen orsulphur.

WO 97/29097 describes sulfonamide derivatives for the treatment ofdisorders in which antagonism of the 5-HT₇ receptor is beneficial. Thesulphur atom is linked to an aromatic group and to a C₁-C₆ alkylsubstituted N atom.

WO97/49695 describes further sulfonamide derivatives in which the Nlinked to the sulphur atom is also fully substituted, for exampleforming part of a piperidine.

WO 03/048118 describes another group of 5HT₇ receptor antagonists. Inthis case aryl and heteroaryl sulfonamide derivatives wherein thesulfonamide group is a substituent on a cycloalkane or cycloalkene ringwhich additionally bears an amino substituent. The N linked to sulphuratom is fully substituted.

WO99/24022 discloses tetrahydroisoquinoline derivatives for use againstCNS disorders and binding to serotonin receptors, in particular 5-HT₇.

WO 00/00472 refers to compounds which are 5-HT7 receptor antagonists.The compounds contain a N-containing fused heterocycle such astetrahydroisoquinoline.

EP 21580 and EP 76072 describe sulfonamide compounds havingantiarrhythmic activity, corresponding to the formulaR₂N(CH₂)_(n)—NH—SO₂R₁, 5-HT₇ activity is not mentioned.

EP 937715 A1 refers to a tetrahydrobenzoindole compound that bindsselectively to a serotonin receptor subtype 5-HT₇ vs 5-HT2.

There is still a need to find compounds that have pharmacologicalactivity towards the receptor 5-HT₇, being both effective and selective,and having good “drugability” properties, i.e. good pharmaceuticalproperties related to administration, distribution, metabolism andexcretion.

SUMMARY OF THE INVENTION

We have now found a family of structurally distinct class of sulfonamidecompounds which are particularly selective inhibitors of the 5-HT₇receptor. The compounds present a2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen moiety, linked through astraight alkylene chain with a sulfonamide moiety. We have found thatthe compounds display IC-50 values in the nM range 1-200 nM at human5-HT7 receptors and exhibit selectivity for these receptors vs 5-HT1A,5-HT2A, 5-HT2B, 5-HT2C, 5-HT3,5-HT4,5-HT5A, D1, D2, D3, D4, adrenergicα1A, α1B, α1B, β1, and β2 receptors.

In one aspect the invention is directed to a compound of the formula I:

whereinW is a substituted or unsubstituted alkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted aryl, substituted or unsubstituted heterocyclyl;R¹, R², R³, R⁴, R^(4B), R⁵, R^(5B), R⁶ and R⁷ are each independentlyselected from the group formed by hydrogen, substituted or unsubstitutedalkyl, substituted or unsubstituted cycloalkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted aryl, substituted orunsubstituted heterocyclyl, —COR⁸, —C(O)OR⁸, —C(O)NR⁸R⁹, —HC═NR⁸, —CN,—OR⁸, —OC(O)R⁸, —S(O)_(t)—R⁸, —NR⁸R⁹, —NR⁸C(O)R⁹, —NO₂, —N═CR⁸R⁹ orhalogen;L is hydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted alkenyl,substituted or unsubstituted aryl, substituted or unsubstitutedheterocyclyl, —COR⁸, —C(O)OR⁸, —C(O)NR⁸R⁹, —HC═NR⁸, —CN, —OR⁸, —OC(O)R⁸,—S(O)_(t)—R⁸, —NR⁸R⁹, —NR⁸C(O)R⁹, or —N═CR⁸R⁹; and the pair R⁴ andR^(4B) or the pair R⁵ and R^(5B) taken together may form a carbonylgroup,t is 1, 2 or 3;R⁸ and R⁹ are each independently selected from hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted alkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heterocyclyl, substituted or unsubstitutedalkoxy, substituted or unsubstituted aryloxy, halogen;n is 2, 3, 4 or 5or a pharmaceutically acceptable salt, isomer, prodrug or solvatethereof.

In another aspect the invention is directed to a pharmaceuticalcomposition which comprises a compound as above defined or apharmaceutically acceptable salt, enantiomer, prodrug or solvatethereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

In a further aspect the invention is directed to the use of a compoundas defined above in the manufacture of a medicament for the treatment ofa 5-HT₇ mediated disease or condition, i.e. diseases caused by failuresin central and peripheral serotonin-controlling functions, such as pain,sleep disorder, shift worker syndrome, jet lag, depression, seasonalaffective disorder, migraine, anxiety, psychosis, schizophrenia,cognition and memory disorders, neuronal degeneration resulting fromischemic events, cardiovascular diseases such as hypertension, irritablebowel syndrome, inflammatory bowel disease, spastic colon or urinaryincontinence.

DETAILED DESCRIPTION OF THE INVENTION

The typical compounds of this invention effectively and selectivelyinhibit the 5-HT7 receptor vs other 5-HT receptors such as 5-HT1A,5-HT2A, 5-HT2B, 5-HT2C, 5-HT3,5-HT4,5-HT5A, D1, D2, D3, D4, adrenergicα1A, α1B, α1B, β1, and β2 receptors, Tachykinin NK-1 opiate, GABA,estrogen, glutamate, adenosine, nicotinic, muscarinic receptors andcalcium, potassium and sodium channels and neurotransmitter transporters(serotonin, dopamine, norepinephrine, GABA).

In the above definition of compounds of formula (I) the following termshave the meaning indicated:

“Alkyl” refers to a straight or branched hydrocarbon chain radicalconsisting of carbon and hydrogen atoms, containing no unsaturation,having one to eight carbon atoms, and which is attached to the rest ofthe molecule by a single bond, e.g., methyl, ethyl, n-propyl, i-propyl,n-butyl, t-butyl, n-pentyl, etc. Alkyl radicals may be optionallysubstituted by one or more substituents such as a aryl, halo, hydroxy,alkoxy, carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro,mercapto, alkylthio, etc. If substituted by aryl we have an “Aralkyl”radical, such as benzyl and phenethyl.

“Alkenyl” refers to an alkyl radical having at least 2 C atoms andhaving one or more unsaturated bonds.

“Cycloalkyl” refers to a stable 3- to 10-membered monocyclic or bicyclicradical which is saturated or partially saturated, and which consistsolely of carbon and hydrogen atoms, such as cyclohexyl or adamantyl.Unless otherwise stated specifically in the specification, the term“cycloalkyl” is meant to include cycloalkyl radicals which areoptionally substituted by one or more substituents such as alkyl, halo,hydroxy, amino, cyano, nitro, alkoxy, carboxy, alkoxycarbonyl, etc.

“Aryl” refers to single and multiple ring radicals, including multiplering radicals that contain separate and/or fused aryl groups. Typicalaryl groups contain from 1 to 3 separated or fused rings and from 6 toabout 18 carbon ring atoms, such as phenyl, naphthyl, indenyl,fenanthryl or anthracyl radical. The aryl radical may be optionallysubstituted by one or more substituents such as hydroxy, mercapto, halo,alkyl, phenyl, alkoxy, haloalkyl, nitro, cyano, dialkylamino,aminoalkyl, acyl, alkoxycarbonyl, etc.

“Heterocyclyl” refers to a stable 3- to 15 membered ring radical whichconsists of carbon atoms and from one to five heteroatoms selected fromthe group consisting of nitrogen, oxygen, and sulfur, preferably a 4- to8-membered ring with one or more heteroatoms, more preferably a 5- or6-membered ring with one or more heteroatoms. For the purposes of thisinvention, the heterocycle may be a monocyclic, bicyclic or tricyclicring system, which may include fused ring systems; and the nitrogen,carbon or sulfur atoms in the heterocyclyl radical may be optionallyoxidised; the nitrogen atom may be optionally quaternized; and theheterocyclyl radical may be partially or fully saturated or aromatic.Examples of such heterocycles include, but are not limited to, azepines,benzimidazole, benzothiazole, furan, isothiazole, imidazole, indole,piperidine, piperazine, purine, quinoline, thiadiazole, tetrahydrofuran,coumarine, morpholine; pyrrole; pyrazole, oxazole, isoxazole, triazole,imidazole, etc.

“Alkoxy” refers to a radical of the formula —ORa where Ra is an alkylradical as defined above, e.g., methoxy, ethoxy, propoxy, etc.

“Alkoxycarbonyl” refers to a radical of the formula-C(O)ORa where Ra isan alkyl radical as defined above, e.g., methoxycarbonyl,ethoxycarbonyl, propoxycarbonyl, etc.

“Alkylthio” refers to a radical of the formula-SRa where Ra is an alkylradical as defined above, e.g., methylthio, ethylthio, propylthio, etc.

“Amino” refers to a radical of the formula-NH2, —NHRa or —NRaRb,optionally quaternized.

“Halo” or “hal” refers to bromo, chloro, iodo or fluoro.

References herein to substituted groups in the compounds of the presentinvention refer to the specified moiety that may be substituted at oneor more available positions by one or more suitable groups, e.g.,halogen such as fluoro, chloro, bromo and iodo; cyano; hydroxyl; nitro;azido; alkanoyl such as a C₁₋₆ alkanoyl group such as acyl and the like;carboxamido; alkyl groups including those groups having 1 to about 12carbon atoms or from 1 to about 6 carbon atoms and more preferably 1-3carbon atoms; alkenyl and alkynyl groups including groups having one ormore unsaturated linkages and from 2 to about 12 carbon or from 2 toabout 6 carbon atoms; alkoxy groups having one or more oxygen linkagesand from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms;aryloxy such as phenoxy; alkylthio groups including those moietieshaving one or more thioether linkages and from 1 to about 12 carbonatoms or from 1 to about 6 carbon atoms; alkylsulfinyl groups includingthose moieties having one or more sulfinyl linkages and from 1 to about12 carbon atoms or from 1 to about 6 carbon atoms; alkylsulfonyl groupsincluding those moieties having one or more sulfonyl linkages and from 1to about 12 carbon atoms or from 1 to about 6 carbon atoms; aminoalkylgroups such as groups having one or more N atoms and from 1 to about 12carbon atoms or from 1 to about 6 carbon atoms; carbocylic aryl having 6or more carbons, particularly phenyl or naphthyl and aralkyl such asbenzyl. Unless otherwise indicated, an optionally substituted group mayhave a substituent at each substitutable position of the group, and eachsubstitution is independent of the other.

Particular individual compounds of the invention include the compounds1-86 in the examples, either as salts or as free bases.

In an embodiment the 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen in thecompounds of formula I above is not substituted, R¹ to R⁷ are all H.Good activity results are obtained with such compounds.

In another embodiment R² and R³ are alkoxy, preferably methoxy and therest of the substitutents of the2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen (R¹ and R⁴ to R⁷) are H.

In another embodiment R² is alkoxy, preferably methoxy and the rest ofthe substitutents of the 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen (R¹and R³ to R⁷) are H.

In another embodiment the group W linked to the sulfonamide is aromatic,such as substituted or unsubstituted aryl, substituted or unsubstitutedheterocyclyl, preferably substituted or unsubstituted phenyl. Goodresults were obtained when W is alkyl, alkoxy and/or halo substitutedphenyl. In particular halo substituted phenyl, having one or more halosubstituents being the same or different are preferred.

In another embodiment it is important that n is 3 or 4.

The above embodiments and preferences for W, R¹ to R⁷ and n can becombined to give further preferred compounds.

Representative compounds of the above embodiments which are preferredare4-Chloro-2,5-dimethyl-N-[4-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-ben-zenesulfonamidehydrochloride,2,5-Dichloro-N-[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamidehydrochloride,2,5-Dichloro-N-[3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride,2-Chloro-N-[3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-4,5-difluoro-benzenesulfonamide hydrochloride.

The compounds of the present invention represented by the abovedescribed formula (I) may include enantiomers depending on the presenceof chiral centres or isomers depending on the presence of multiple bonds(e.g. Z, E). The single isomers, enantiomers or diastereoisomers andmixtures thereof fall within the scope of the present invention.

Unless otherwise stated, the compounds of the invention are also meantto include compounds which differ only in the presence of one or moreisotopically enriched atoms. For example, compounds having the presentstructures except for the replacement of a hydrogen by a deuterium ortritium, or the replacement of a carbon by a ¹³C— or 14C-enriched carbonor ¹⁵N-enriched nitrogen are within the scope of this invention.

The term “pharmaceutically acceptable salts, solvates, prodrugs” refersto any pharmaceutically acceptable salt, ester, solvate, or any othercompound which, upon administration to the recipient is capable ofproviding (directly or indirectly) a compound as described herein.However, it will be appreciated that non-pharmaceutically acceptablesalts also fall within the scope of the invention since those may beuseful in the preparation of pharmaceutically acceptable salts. Thepreparation of salts, prodrugs and derivatives can be carried out bymethods known in the art.

For instance, pharmaceutically acceptable salts of compounds providedherein are synthesized from the parent compound which contains a basicor acidic moiety by conventional chemical methods. Generally, such saltsare, for example, prepared by reacting the free acid or base forms ofthese compounds with a stoichiometric amount of the appropriate base oracid in water or in an organic solvent or in a mixture of the two.Generally, nonaqueous media like ether, ethyl acetate, ethanol,isopropanol or acetonitrile are preferred. Examples of the acid additionsalts include mineral acid addition salts such as, for example,hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate,and organic acid addition salts such as, for example, acetate, maleate,fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate,methanesulphonate and p-toluenesulphonate. Examples of the alkaliaddition salts include inorganic salts such as, for example, sodium,potassium, calcium, ammonium, magnesium, aluminium and lithium salts,and organic alkali salts such as, for example, ethylenediamine,ethanolamine, N,N-dialkylenethanolamine, triethanolamine, glucamine andbasic aminoacids salts.

Particularly favored derivatives or prodrugs are those that increase thebioavailability of the compounds of this invention when such compoundsare administered to a patient (e.g., by allowing an orally administeredcompound to be more readily absorbed into the blood) or which enhancedelivery of the parent compound to a biological compartment (e.g., thebrain or lymphatic system) relative to the parent species.

Any compound that is a prodrug of a compound of formula (I) is withinthe scope of the invention. The term “prodrug” is used in its broadestsense and encompasses those derivatives that are converted in vivo tothe compounds of the invention. Such derivatives would readily occur tothose skilled in the art, and include, depending on the functionalgroups present in the molecule and without limitation, the followingderivatives of the present compounds: esters, amino acid esters,phosphate esters, metal salts sulfonate esters, carbamates, and amides.

The compounds of the invention may be in crystalline form either as freecompounds or as solvates and it is intended that both forms are withinthe scope of the present invention, Methods of solvation are generallyknown within the art. Suitable solvates are pharmaceutically acceptablesolvates. In a particular embodiment the solvate is a hydrate.

The compounds of formula (I) or their salts or solvates are preferablyin pharmaceutically acceptable or substantially pure form. Bypharmaceutically acceptable form is meant, inter alia, having apharmaceutically acceptable level of purity excluding normalpharmaceutical additives such as diluents and carriers, and including nomaterial considered toxic at normal dosage levels. Purity levels for thedrug substance are preferably above 50%, more preferably above 70%, mostpreferably above 90%. In a preferred embodiment it is above 95% of thecompound of formula (I), or of its salts, solvates or prodrugs.

Compounds of Formula (I) can be prepared by the coupling of a compoundof Formula (II):

in which R¹-R⁷, L and n are as defined in Formula (I), with a compoundof Formula (III):

in which W is as defined in Formula (I) and X is an halogen, typicallyCl.

The reaction of compounds of formulas (II) and (III) is preferablycarried out in an aprotic solvent, but not limited to, such asdichloromethane in the presence of an organic base, such asdiisopropylethylamine or triethylamine.

Compounds of Formula (III) are commercially available or can be preparedby conventional methods.

Compounds of Formula (II) can be prepared from compounds of Formula (IV)or compounds of Formula (V) using the reactions described below.

The preparation of these two compounds are later described in the text.

Compounds of Formula (II) from Compounds of Formula (IV):

If L=CH₂L′ compounds of Formula (IV) can be acylated with a carboxylicacid derivative (L′COX), where X is a good leaving group, such ashalogen (Cl or Br) or with an anhydride of L′ (L′COOCOL′), followed by areduction (Scheme 1). The acylation can be done in the presence of anappropriate base, such as pyridine and a solvent such asdichloromethane, or using a bifasic system consisting of a mixture ofdichloromethane/water using an inorganic base such as NaHCO₃. Thereduction of the carbonyl group can be afforded by an hydride, such asLiAlH₄.

If L is alkyl or cycloalkyl, compounds of Formula (II) can also beobtained by an alkylation of IV with a variety of alkyl compoundscontaining a good leaving group such as Br, I, aryl or alkylsulfonate inthe presence of an appropriate base and solvent, as shown in Scheme 2.Useful bases include, but are not limited to, metal carbonates orbicarbonates (NaHCO₃, K₂CO₃ . . . ) Typical solvents include polaraprotic liquids such as DMF or THF.

If L is aryl or heteroaryl, the N-arylation can be achieved by a crosscoupling reaction with X-L, where X is a halogen or alkyl or arylsulfonate, using a catalytic system consisting of a metal, such as Pd,Cu and a ligand such as phosphine, in the presence of a dry solvent suchas toluene or dioxane and an appropriate base such as Cs₂CO₃ or tBuOK(Scheme 3).

Compounds of Formula (II) from compounds of Formula (V):

The synthesis can be done in a sequential way by treatment of the amineof Formula (V) with a dialkylating agent (VI) in the presence of a basein an appropriate solvent, followed by the alkylation of a primary aminesubstituted with L (VII). This sequence is illustred in Scheme 4.

Examples of useful alkylating agents are those where Y is a good toexcellent leaving group, such as Br, I, aryl or alkylsulfonate and X isa good leaving group, such as Br or Cl. Useful bases include, but arenot limited to, metal carbonates such as K₂CO₃ or Cs₂CO₃, metalhydroxides, hindered alkoxides or tertiary organic amines. Typicalsolvents include polar aprotic liquids such as DMF or THF, or proticliquids such as alcohols. The rate of the second alkylation may beenhaced, particulary when X is Cl, by the addition of a catalytic amountof a iodide salt, such as NaI or KI.

Compounds of Formula (II) can also be prepared from compounds of Formula(V) by an alkylation with a secondary amine substituted with L and withan alkyl chain containing a good leaving group, such as Br, I, alkyl oraryl sulfonate (VIII) In Scheme 5, the amino group of VIII should beprotected to avoid side reactions. Some examples of protecting groupsinclude a variety of carbamates, such as BOC; Fmoc . . . a variety ofamides, such as acetamides, and alkyl and aryl amine derivatives, suchas N-benzyl, N-allyl . . . Deprotection of these protecting groups maybe performed using conventional methods. The alkylation can be doneusing the same solvents, and bases described above. The protection ofthe amino group of compounds of Formula (VIII) can be avoided if itsreactivity is much lower than the reactivity of the amino group ofcompounds of Formula (V).

Another way to some compounds of Formula (II) from compounds of Formula(V) (Scheme 6) can be by an alkylation with haloalkylamides (IX) in anappropriate solvent and base, the same as are cited in Schemes above.Intermediate (X) may be reduced in the presence of a hydride, such asLiAlH₄ or borane.

An alternative way to compounds of Formula (II) from compounds ofFormula (V) (Scheme 7) can be achieved using compounds of Formula (XI)and a condensating agent such as N,N-dicyclohexylcarbodiimide (DCC) or1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC),carbonyldiimadazole,O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate(HBTU) or benzotriazol-N-oxotris(dimethylamino) phosphoniumhexafluorophosphate (BOP)), among others, in the presence of an aproticsolvent, such as DMF and an organic base, such as triethylamine. Then, areduction of the two amide groups of compounds of Formula (XII) in a drysolvent, such as tetrahydrofurane, in the presence of an hydride, suchas LiAlH₄, can lead to compounds of Formula (II), as shown in Scheme 7.

Preparation of Compounds of Formula (V):

Amines of Formula (V) can be prepared by methods and techniquesdescribed below. References for cited described methods areincorporated.

A variety of substituted compounds of Formula (V) shown in Scheme 8 canbe achieved from compounds of Formula (Va). Total reduction from thisketone by hydrogenation at high pressure in the presence of concentratedacid, such as HCl, or with hydrazine in a Wolff-Kischner reaction, orusing Clemensen-type conditions with HCl and Zn can lead to compounds ofFormula (Vb). Partial reduction with an hydride, such as NaBH₄, can leadto the alcohol of Formula (Vc), which can also be reduced to compoundsof Formula (Vb) by a hydrogenation.

The introduction of substitution in the ketone (Va) can be done, amongothers, by a nucleophilic attack with organometallics, such as lithiumreagents (R^(4B)Li) to yield the compound (Vd), by reductive aminationwith an amine (RR′NH) and an hydride such as NaBH(OAc)₃ to yield (Ve),or by C—C bond formation with phosphonium ylides phosphonates in aWittig-type reaction to yield (Vf) . . . . Some of these methods needthe protection of the amino group. The protecting groups used can bethose which have been descrived above. All these compounds can befurther derivatized using conventional organic reactions.

Compounds of Formula (Va) can be obtained from a β-aminoacid (XIII) by aFriedel-Crafts acylation (Scheme 9). This acylation can be carried outin the presence of a strong acid, such as polyphosphoric acid,methanesulfonic acid . . . or a Lewis acid, such as AlCl₃ . . . at hightemperature (100-200° C.). Unsubstituted compound of Formula (Va),2a,3,4,5-Tetrahydro-2H-3-aza-acenaphthylen-1-one, can be prepared from2-(1,2,3,4-tetrahydroisoquinolin-1-yl)acetic acid, according the methodsdescribed in J. Org. Chem. 1987, 52, 616-622 and in Heterocycles, 1989,29(12), 2399-2402. Nevertheless, these methods have been improved by theuse of microwave radiation instead of conventional heating (see exampleslater in the text).

The β-aminoacid (XIII) can be prepared by a sequential or one-potsynthesis starting from substituted phenylethyl amines.

The multi-step synthesis (Scheme 10) can start with a Pictet-Spenglerreaction with formaldehyde to yield a substituted tetrahydroisoquinoline(XIV). The oxidation of the benzylic position α to the N can be achievedby a bromination with NBS followed by an elimination in the presence ofa base to yield a substituted dihydroisoquinoline (XV). An aldolicreaction with a α,α-disubstituted acetic acid with R⁵ and R^(5B) canlead to the β-aminoacid (XIII).

This reaction is especially favoured when a substituted malonic acid isused, because of a decarboxylation process at high temperature (100-150°C.), but then, only one substitution (R⁵ or R^(5B)) can be introduced.The other substitution has to be necessarily a H, as shown in Scheme 11.

The one-pot synthesis can also be performed by a Pictet-Spenglerreaction, in the presence of 3-oxopropanoic acid derivativeα,α-disubstituted with R⁵ and R^(5B) (Scheme 12)

Other possible way to compounds of Formula (V) is starting from aphenylethyl amine and a malonic acid derivative α,α-disubstituted withR⁵ and R^(5B) by a Bischler-Napieralsky reaction, as shown in Scheme13a). The selective reduction of the imine bond of compound of Formula(XVI) can lead to the desired compounds of Formula (V), which could befurther derivatized. This method also allows to achieve chiral compoundsof Formula (V) if the reduction step consists of an asymmetrichydrogenation catalyzed by complexes formed by a transition methal, suchas rhodium or ruthenium and a chiral ligand, such as phosphine orphosphane. Methodologies for an asymmetric hydrogenation of ketones orimines are described in J. Am. Chem. Soc. 1996, 118, 4916, J. Am. Chem.Soc. 1996, 118, 5142, J. Org. Chem. 1998, 63, 6084. Another suitablemethod for the obtention of a chiral compound of Formula (Va) or (V) isshown in Scheme 13 b). Starting from a isoquinoline, a enantioselectiveacyl-Mannich-type reaction is catalyzed by a chiral thiourea derivativeto give a chiral dihydroisoquinoline, which can lead to compound ofFormula (Va) by a hydrolisis, deprotection of the nitrogen atom (Angew.Chem. Int. Ed. 2005, 44, 6700-6704) and a cyclization by aFriedel-Crafts acylation (Scheme 9).

Where convenient, a variety of substituted compounds of Formula (V) canbe achieved from compounds of Formula (XVII) by the multi-step synthesisshown in Scheme 14. Compounds of Formula (XVII) are commerciallyavailable or prepared by conventional methods.

The sequence can start with a reductive amination of compounds ofFormula (XVII) with an aminoketal substituted with R⁶ and R⁷. The use ofketals instead of unprotected aldehydes or ketones is convenient toavoid side-reactions, such as polymerization of the bifunctionalyzedamines. The reduction of the resulting imine (XVIII) by hydrogenationlead to the aminoketal (XIX). The hydrolysis of the ketal in acid media,such as hydrochloric acid lead to a keto compound (XX) or directly tothe dihydroisoquinoline (XXI), which can be reduced by a hydrogenationto yield the desired compounds of Formula (V). The preparation by thismethod of the unsubstituted compound of Formula (Va),1,2,2a,3,4,5-Hexahydro-2H-3-aza-acenaphthylen, and the compoundsubstituted with R²═R³═oCH₃,7,8-Dimethoxy-1,2,2a,3,4,5-hexahydro-3-aza-acenaphthylene, is describedin J. Org. Chem. 1971, 36(1), 111-117.

Preparation of Compounds of Formula (Iv):

Compounds of Formula (IV) can be prepared from compounds of Formula (V)using the reactions and techniques described below.

The reactions are performed in a solvent appropriate to the reagents andmaterials employed and suitable for the transformations. Thefunctionality present on the molecule should be consistent with thetransformations proposed. This will sometimes require a selection of aparticular process scheme over another in order to obtain the desiredcompound of the invention. Preferred methods included, but are notlimited to, those described below.

Compounds of Formula (IV) can be prepared by alkylation as shown inScheme 15.

In the first step, the amine of Formula (V) is allowed to react with acommercially available N-(n-haloalkyl)phtalimide (XXII) in the presenceof an appropriate base and solvent. Useful bases include, but are notlimited to, metal carbonates such as K₂CO₃ or Cs₂CO₃, metal hydroxides,hindered alkoxides or tertiary organic amines. Typical solvents includepolar aprotic liquids such as DMF of THF, or protic liquids such asalcohols. In a second step, the hydrazinolysis of the alkylated compound(XXIII) using hydrazine in a polar protic solvent, such as ethanol, andhydrochloric acid gives the desired compound of Formula (IV).

A similar route to compounds of Formula (IV) is illustrated in Scheme16.

The acylation of compounds of Formula (V) with carboxyalkylphtalimidesderivatives (XXIV), instead of the alkylation withN-(n-haloalkyl)phtalimides (XXII), may be convenient in some cases. WhenX is a Cl or Br, or other good leaving group, the base used foracylation can be a tertiary organic amine such as triethylamine orN,N-diisopropylethylamine and the hydrazinolysis can be performed ascited in Scheme 15. When X is an OH, a coupling reagent must be used forthe activation of carboxy group. Many coupling reagents are known in theliterature to form amide bonds from carboxylic acids and amines,including DCC, EDC, HBTU, TBTU, BOP, PyBOP . . . . Appropriate bases forsuch coupling reactions include tertiary amines such asN,N-diisopropylethylamine, triethylamine . . . . The activated speciesare usually not isolated, but are allowed to react in situ with theamine partner (V).

After the hydrazinolysis of phtalimide (XXV), the reduction of the amideintermediate (XXVI) may be performed with a reducing agent, such asborane or lithium aluminum hydride in appropriate solvent, typicallyTHF.

A similar method to compounds of Formula (IV) is illustrated in Scheme17.

A reductive amination with phtalimidoalkylaldehydes (XXVII), followingby hydrazinolysis may also be performed. Condensation of the amine (V)with aldehydes (XXVII) can be performed in the presence of a hydride,such as sodium triacethoxyborohydride NaBH(OAc)₃ or sodiumcyanoborhydride (NaBH₄CN). Phtalimide intermediate (XXVIII) is treatedas is described in Schemes 15 and 16 in order to obtain the desiredcompound of Formula (IV).

In all these Schemes, other protecting groups for the nitrogen atom,instead of the phtalimide, may be used. Some examples include othercyclic imide derivatives, such as maleimides or succinimides, a varietyof carbamates, such as BOC (an example is illustred in Scheme 18); Fmoc. . . a variety of amides, such as acetamides, and alkyl and aryl aminederivatives, such as N-benzyl, N-allyl . . . . Deprotection of theseprotecting groups may be performed using conventional methods.

This Scheme is especially useful in the case where R⁴ and R^(4B)together form a keto group, in order to avoid the reduction steps neededin the Schemes above, for the deprotection of the amino group of thealkylic chain, which can alter the ketone.

Where convenient, compounds of Formula (IV) can be prepared as shown inScheme 19.

The alkylation of compounds of Formula (V) with commercially availablehaloalkylnitriles (XXIX) can be performed in the presence of a varietyof bases and solvents cited in schemes above. For the reduction of thecyano group of (XXX), common reducing agents, such as LiAlH₄ in THF, canbe used. A catalytic hydrogenation with Pdd/C in ethanol is alsopossible.

In some cases, an acylation with carboxynitriles to form an amide ispreferred instead of the alkylation with the corresponding halonitriles(Scheme 20).

The acylation of compounds of Formula (V) with compounds of Formula(XXXI), where X is a good leaving group, such as Cl or Br, is carriedout in the presence of an appropriate base and solvent, which weredescribed in schemes above. The reduction of cyano and keto group ofXXXII can be performed simultaneously in the presence of an excess of areducing agent such as LiAlH₄ or borane. When X is OH, a couplingreagent must also be used for the activation of carboxy group. Thecoupling reagents used are the same as are cited in Scheme 16.

Scheme 20 is also possible when X is an H. Reductive amination iscarried out by a condensation of amine of Formula (V) with aldehyde ofFormula XXXI in appropriate base and solvent, to form an imine orenamine intermediate, followed by a reduction with a reducing agent,such an hydride.

Preparation of Compounds of Formula (I) from Compounds of Formula (Ib):

When L=aryl or heteroaryl, compounds of Formula (I) can also be obtainedby the coupling of compounds of Formula (Ib), with an aryl or heteroarylcontaining an electrowithdrawing and good leaving group (Y), such as ahalogen or alkyl or aryl sulfonate, using catalytic cross couplingreaction conditions (Scheme 21). Compounds of Formula (Ib) can besynthesized by the coupling of compounds of Formula (IV) with compoundsof Formula (III) following the methods described for the preparation ofcompounds of Formula (I) when L=H.

In some cases, although L=alkyl or cycloalkyl, compounds of Formula (I)can also be conveniently prepared from compounds of Formula (Ib), by analkylation of the nitrogen of the sulfonamide group, using, an strongbase, such as NaH in an aprotic and dry solvent, such as THF, in thepresence of an alkylating agent, such as ethyl iodide as shown in Scheme22.

This Scheme is especially useful in the case where R⁴ and R^(4B)together form a keto group, in order to avoid the reduction steps neededin other Schemes, which can alter the ketone. When R⁴ and R^(4B)together form a keto group, Scheme 2 (see above) is also a suitablemethod to obtain compounds of Formula (II) from compounds of Formula(IV).

Nevertheless, if R₄ and R_(4B) together form a keto group, compounds ofFormula (I) can also be prepared using all the methods described in theSchemes above, but using protecting groups for the keto group, in orderto avoid the reduction of this group in the steps where other reductionis required. Some examples include acyclic ketals, such as dimethyl ordiisopropyl, or cyclic ketals, such as 1,3-dioxanes or 1,3-dioxolanes.Protection and deprotection steps may be performed using conventionalmethods.

The following Descriptions and Examples illustrate the preparation ofcompounds of the invention.

The obtained reaction products may, if desired, be purified byconventional methods, such as crystallisation, chromatography andtrituration. Where the above described processes for the preparation ofcompounds of the invention give rise to mixtures of stereoisomers, theseisomers may be separated by conventional techniques such as preparativechromatography. If there are chiral centers the compounds may beprepared in racemic form, or individual enantiomers may be preparedeither by enantiospecific synthesis or by resolution.

One preferred pharmaceutically acceptable form is the crystalline form,including such form in pharmaceutical composition. In the case of saltsand solvates the additional ionic and solvent moieties must also benon-toxic. The compounds of the invention may present differentpolymorphic forms, it is intended that the invention encompasses allsuch forms.

Another aspect of this invention relates to a method of treating orpreventing an 5-HT₇ mediated disease which method comprisesadministering to a patient in need of such a treatment a therapeuticallyeffective amount of a compound of formula (I) or a pharmaceuticalcomposition thereof. Among the 5-HT₇ mediated diseases that can betreated are diseases caused by failures in central and peripheralserotonin-controlling functions, such as pain, sleep disorder, shiftworker syndrome, jet lag, depression, seasonal affective disorder,migraine, anxiethy, psychosis, schizophrenia, cognition and memorydisorders, neuronal degeneration resulting from ischemic events,cardiovascular diseases such as hypertension, irritable bowel syndrome,inflammatory bowel disease, spastic colon or urinary incontinence.

The present invention further provides pharmaceutical compositionscomprising a compound of this invention, or a pharmaceuticallyacceptable salt, derivative, prodrug or stereoisomers thereof togetherwith a pharmaceutically acceptable carrier, adjuvant, or vehicle, foradministration to a patient.

Examples of pharmaceutical compositions include any solid (tablets,pills, capsules, granules etc.) or liquid (solutions, suspensions oremulsions) composition for oral, topical or parenteral administration.

In a preferred embodiment the pharmaceutical compositions are in oralform, either solid or liquid. Suitable dose forms for oraladministration may be tablets, capsules, syrops or solutions and maycontain conventional excipients known in the art such as binding agents,for example syrup, acacia, gelatin, sorbitol, tragacanth, orpolyvinylpyrrolidone; fillers, for example lactose, sugar, maize starch,calcium phosphate, sorbitol or glycine; tabletting lubricants, forexample magnesium stearate; disintegrants, for example starch,polyvinylpyrrolidone, sodium starch glycollate or microcrystallinecellulose; or pharmaceutically acceptable wetting agents such as sodiumlauryl sulfate.

The solid oral compositions may be prepared by conventional methods ofblending, filling or tabletting. Repeated blending operations may beused to distribute the active agent throughout those compositionsemploying large quantities of fillers. Such operations are conventionalin the art. The tablets may for example be prepared by wet or drygranulation and optionally coated according to methods well known innormal pharmaceutical practice, in particular with an enteric coating.

The pharmaceutical compositions may also be adapted for parenteraladministration, such as sterile solutions, suspensions or lyophilizedproducts in the appropriate unit dosage form. Adequate excipients can beused, such as bulking agents, buffering agents or surfactants.

The mentioned formulations will be prepared using standard methods suchas those described or referred to in the Spanish and US Pharmacopoeiasand similar reference texts.

Administration of the compounds or compositions of the present inventionmay be by any suitable method, such as intravenous infusion, oralpreparations, and intraperitoneal and intravenous administration. Oraladministration is preferred because of the convenience for the patientand the chronic character of the diseases to be treated.

Generally an effective administered amount of a compound of theinvention will depend on the relative efficacy of the compound chosen,the severity of the disorder being treated and the weight of thesufferer. However, active compounds will typically be administered onceor more times a day for example 1, 2, 3 or 4 times daily, with typicaltotal daily doses in the range of from 0.1 to 1000 mg/kg/day.

The compounds and compositions of this invention may be used with otherdrugs to provide a combination therapy. The other drugs may form part ofthe same composition, or be provided as a separate composition foradministration at the same time or at different time.

The following examples are given only as further illustration of theinvention, they should not be taken as a definition of the limits of theinvention.

EXAMPLES

Compounds of general Formula (I) were prepared by means of conventionalorganic chemistry methods known to those skilled in the art and someexamples are described below. The preparation of some of theintermediates of general formulas (V), (IV) and (II) is also shownbelow.

Example A

This is an example of a compound of general Formula (Va).2a,3,4,5-Tetrahydro-2H-3-aza-acenaphthylen-1-one can be prepared from2-(1,2,3,4-tetrahydroisoquinolin-1-yl)acetic acid, according the methodsdescribed in J. Org. Chem. 1987, 52, 616-622 and in Heterocycles, 1989,29(12), 2399-2402, which are hereby incorporated by reference and formpart of the disclosure. Nevertheless, these methods were improved by theuse of microwave radiation instead of conventional heating.

2a,3,4,5-Tetrahydro-2H-3-aza-acenaphthylen-1-one

Polyphosphoric acid (30 g) was added to a suspension of2-(1,2,3,4-tetrahydroisoquinolin-1-yl)acetic acid (2 g) in1,1,2,2-tetrachloroethane (6 ml) and the mixture was allowed to react ina CEM Explorer microwave apparatus working at 150° C. and at 150 W for45 min. The crude was poured to a mixture of ice/water to destroy thePPA, made alkaline with 25% ammonia and extracted with dichloromethane.The combined organic layers were dried with Na₂SO₄ and evaporated invacuo to afford a brown solid (1.7 g, 94% yield), which was purified bysilicagel chromatography using a gradient of dichloromethane/methanol toafford a light brown solid identified as2a,3,4,5-Tetrahydro-2H-3-aza-acenaphthylen-1-one.

¹H NMR (300 MHz, CHLOROFORM-D) δ ppm 2.47 (dd, J=17.13, 6.30 Hz, 1H)2.55 (s, 1H) 2.90 (m, 2H) 2.99 (dd, J=17.06, 6.66 Hz, 1H) 3.25 (ddd,J=12.70, 9.11, 7.32 Hz, 1H) 3.44 (ddd, J=12.74, 5.56, 3.22 Hz, 1H) 4.21(t, J=6.37 Hz, 1H) 7.29 (m, 2H) 7.45 (t, J=4.25 Hz, 1H)

MS (APCI (M+H)⁺): 174

Example B

This is an example of a compound of general Formula (V).1,2,2a,3,4,5-Hexahydro-3-aza-acenaphthylen can be prepared according themethod described in J. Med. Chem. 1988, 31(2), 433-443, or according themethod described in Heterocycles, 1989, 29(12), 2399-2402, which arehereby incorporated by reference and form part of the disclosure. Thesemethods have been slightly modified in order to obtain a better yield inonly one-step.

1,2,2a,3,4,5-Hexahydro-3-aza-acenaphthylene hydrochloride

A solution of 2a,3,4,5-Tetrahydro-2H-3-aza-acenaphthylen-1-one (2 g,11.5 mmol) in 6 N hydrochloric acid (150 ml) containing 10% Pd/C washydrogenated at 50 psi of H₂ for 24 h. The catalyst was filtered, thesolution was basified with 20% NaOH and extracted with dichloromethane(3×150 ml). The organic layers were dried over Na₂SO₄ and concentratedto dryness to afford a colorless oil (1.6 g, 85% yield) identified as1,2,2a,3,4,5-Hexahydro-3-aza-acenaphthylene. The addition of 2.8 Nhydrochloric acid in ethanol yielded the hydrochloride as a white solid,which was collected by filtration.

¹H NMR (300 MHz, CHLOROFORM-D) 8 ppm 1.69 (qd, J=11.23, 8.30 Hz, 1H)2.46 (m, 1H) 2.75 (m, 3H) 2.88 (m, 1H) 3.16 (ddd, J=12.82, 10.50, 6.23Hz, 1H) 3.43 (ddd, J=12.82, 6.23, 1.95 Hz, 1H) 4.06 (dd, J=10.62, 6.47Hz, 1H) 6.93 (d, J=7.32 Hz, 1H) 7.04 (m, 1H) 7.12 (t, J=7.32 Hz, 1H)

MS (APCI (M+H)⁺): 160

Example C

This is an example of a compound of general Formula (IV) from a compoundof general formula (V).

2,3-Dihydro-benzofuran-5-sulfonic acid[3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthy-len-3-yl)-propyl]-amidehydrochloride a)2-[3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-isoindole1,3-dione

mixture of 1,2,2a,3,4,5-Hexahydro-3-aza-acenaphthylene (1.1 g, 6.92mmol), N-(4-Bromopropyl)phtalimide (1.97 g, 7.33 mmol) and potassiumcarbonate (2.8 g, 20.76 mol) in dry N,N′-dimethylformamide (10 mL), wasstirred overnight at room temperature. The mixture was vacuumconcentrated and the residue was dissolved in water (10 mL), extractedwith ethyl acetate (3×10 mL) and washed with water. The organic layerwas dried and evaporated to give the product (2.20 g, 92% yield).

¹H NMR (300 MHz, DMSO-D6) δ ppm 1.48-1.64 (m, 1H) 1.85 (dt, J=13.66,6.87 Hz, 2H) 2.15-2.27 (m, 2H) 2.27-2.38 (m, 1H) 2.63-2.78 (m, 4H) 3.15(dd, J=11.72, 5.86 Hz, 1H) 3.21-3.29 (m, 1H) 3.54-3.71 (m, 2H) 6.83 (d,J=6.88 Hz, 1H) 6.94-7.08 (m, 2H) 7.75-7.87 (m, J=11.57, 9.19, 4.21, 2.42Hz, 4H)

MS (APCI (M+H)⁺): 347

b) 3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propylaminedihydrochloride

A solution of2-[3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-isoindolel,3-dione(2 g, 5.78 mmol) and hydrazine hydrate (2.9 g, 57.8 mol) in ethanol (60mL) was refluxed for 1 h. The reaction mixture was cooled down andtreated with an additional amount of ethanol (30 mL) and concentratedHCl (7 mL). Then the reaction mixture was refluxed for 4 h and leftovernight in a refrigerator. The precipitate was filtered off, and thesolvent was evaporated. The residue was redissolved in water (15 ml) andmade alkaline with 25% ammonia. Then, was extracted with CH₂Cl₂ (3×120mL), the organic layer was dried over Na₂SO₄, and evaporated to dryness.The crude was dissolved in ethylacetate. A 2.8 M solution of hydrogenchloride in ethanol was then added. The precipitate formed was collectedby filtration to give the desired product (0.80 g, 64% yield) as a beigesolid.

¹H NMR (300 MHz, DMSO-D6) δ ppm 2.14 (m, 3H) 2.63 (m, 1H) 2.90 (m, 4H)3.15 (m, 3H) 3.48 (m, 2H) 3.80 (m, 1H) 4.59 (m, 1H) 7.07 (d, J=7.47 Hz,1H) 7.16 (d, J=7.47 Hz, 1H) 7.25 (t, J=7.47 Hz, 1H) 8.22 (s, 2H) 10.99(br, 1H)

MS (APCI (M+H)⁺): 217

Example D

This is an example of a compound of general Formula (II) from a compoundof general formula (V).

[3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-m-tolyl-aminea) 3-(3-Chloro-propyl)-1,2,2a,3,4,5-hexahydro-3-aza-acenaphthylene

To a solution of 1,2,2a,3,4,5-Hexahydro-3-aza-acenaphthylenehydrochloride (500 mg, 2.56 mmol) in dry N,N′-dimethylformamide (5 ml)was added NaHCO₃ (620 mg, 12.8 mmol) and 1-bromo-3-chloropropyl (420 mg,2.68 mmol) and the mixture was stirred overnight at room temperature.The mixture was vacuum concentrated and the residue was dissolved inwater (15 mL), extracted with ethyl acetate (3×15 mL) and washed withwater. The organic layer was dried and evaporated to give the desiredproduct (250 mg, 70% yield).

MS (APCI (M+H)⁺): 236

b)[3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-m-tolyl-aminedihydrochloride

To a solution of m-tolylamine (21.7 mg, 0.20 mmol) in dry DMF (2 ml) wasadded K₂CO₃ (31 mg, 0.22 mmol), NaI (33 mg, 0.22 mmol) and3-(3-Chloro-propyl)-1,2,2a,3,4,5-hexahydro-3-aza-acenaphthylene (50 mg,0.21 mmol) and the mixture was stirred overnight at 90° C. The mixturewas vacuum concentrated and the residue was dissolved in water (5 mL),extracted with ethyl acetate (3×5 mL) and washed with water. The organiclayer was dried and evaporated. The residue was dissolved in ethylacetate (1 ml) and 2.8 N hydrochloric acid was added. A light brownsolid precipitate, which was collected by filtration to give the desiredproduct (40 mg, 66% yield).

¹H NMR (300 MHz, DMSO-D6) δ ppm 2.09 (m, 3H) 2.25 (s, 3H) 2.61 (m, 1H)2.88 (d, J=7.82 Hz, 2H) 3.10 (m, 2H) 3.24 (m, 2H) 3.41 (m, 2H) 3.82 (m,2H) 4.60 (m, 1H) 6.82 (m, 2H) 7.07 (d, J=7.42 Hz, 1H) 7.16 (m, 2H) 7.25(m, 2H)

MS (APCI (M+H)⁺): 307

Example E

This is an example of a compound of general Formula (II) from a compoundof general Formula (IV).

Ethyl-[3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-aminea)N-[3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-acetamide

3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propylamine (516 mg,2.39 mmol) was disolved in a vigorously stirred mixture of CH₂Cl₂ (2.7ml) and NaHCO₃ (sat. solution, 2.7 ml). After the addition of aceticanhydride (348.9 mg, 3.42 mmol), stirring was applied for 90 min at roomtemperature. Then, the layers were separated. Water (6 ml) was added tothe bicarbonate layer and was extracted with CH₂Cl₂ (3×6 ml). Thecombined organic layers were dried with Na₂SO₄, filtered and evaporatedtoo dryness to afford as slightly brown solid identified as theacetylated compound (535 mg, 87% yield).

¹H NMR (300 MHz, DMSO-D6) δ ppm 1.58 (m, 3H) 1.75 (s, 3H) 2.17 (m, 2H)2.36 (m, 1H) 2.71 (m, 5H) 3.04 (ddd, J=12.60, 6.96, 3.00 Hz, 2H) 3.16(m, 1H) 3.28 (m, 1H) 6.87 (d, J=7.18 Hz, 1H) 7.02 (m, 2H) 7.80 (br, 1H)

MS (APCI (M+H)⁺): 259

b) Ethyl-[3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-aminedihydro-chloride

N-[3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-acetamide(478 mg, 1.85 mmol) was dissolved in THF (dry, 13 ml) and added dropwiseto a suspension of 1 M LiALH₄ (3.7 ml, 3.7 mmol) in dry THF under argonatmosphere. The mixture was refluxed overnight. Water and 1 N NaOH wasadded to the crude. The salts formed were filtered over Celite and thefiltrate was extrated with CH₂Cl₂, dried with Na₂SO₄ and evaporated invacuo. The colorless oil obtained (427 mg, 94% yield) was purified bysilicagel chromatography using a gradient of CH₂Cl₂/methanol. A 2.8 Msolution of hydrogen chloride in ethanol was then added. The precipitateformed was collected by filtration to give the desired product (436 mg,75% yield) as a white solid.

¹H NMR (300 MHz, DMSO-D6) 8 ppm 1.21 (t, J=7.18 Hz, 3H) 2.14 (m, 3H)2.65 (m, 1H) 2.91 (m, 6H) 3.17 (m, 3H) 3.48 (m, 2H) 3.84 (d, J=11.28 Hz,1H) 4.60 (m, 1H) 7.08 (d, J=7.32 Hz, 1H) 7.17 (d, J=7.18 Hz, 1H) 7.26(m, 1H) 9.17 (br, 2H) 10.88 (br, 1H)

MS (APCI (M+H)⁺): 245

Example F

This is an example of a compound of general Formula (II) from a compoundof general Formula (V).

Ethyl-[3-(7,8-Dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-aminea)N-[3-(7,8-Dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-3-oxo-propyl]-acetamide

A suspension of N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (1.14 g, 5.93 mmol) and triethylamine (4 ml) inN,N-Dimethylformamide (30 ml) is stirred at room temperature. Then,1-Hydroxybenzotriazole (0.698 g, 4.56 mmol),7,8-Dimethoxy-1,2,2a,3,4,5-hexahydro-3-aza-acenaphthylene hydrochloride(1.0 g, 4.56 mmol) and N-acetil-3-aminopropanoic acid (0.657 g; 5.0mmol) were added and the crude is stirred at room temperature for 15 h.Then, water (60 ml) and CH₂Cl₂ (60 ml) are added to the crude. Organiclayer is separated and the aqueous one is extracted with CH₂Cl₂ (2×60ml). All the organic layers were collected and washed with 0.1 N HCl(3×60 ml), with NaHCO₃ (3×60 ml) sat and with water (3×40 ml). Afterdrying with Na₂SO₄, filtration and vacuum concentration, a beige oil isobtained (1.32 g, 87% yield). The oil is cristallized in ethyl acete togive a beige solid (1.0 g, 66% yield).

¹H NMR (300 MHz, DMSO-D6) δ ppm 1.76 (s, 3H) 2.46 (m, 2H) 2.60 (m, 4H)2.81 (m, 3H) 3.25 (m, 2H) 3.70 (s, 3H) 3.72 (s, 3H) 3.95 (m, 1H) 4.68(m, 1H), 6.72 (s, 1

H) 7.88 (t, J=5.35 Hz, 1H)

MS (APCI (M+H)⁺): 333

b)Ethyl-[3-(7,8-Dimethoxy-2,2a-4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-aminedihydrochloride

N-[3-(7,8-Dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-3-oxo-propyl]acetamide(370 mg, 1.1 mmol) was dissolved in THF (dry, 10 ml) and added dropwiseto a suspension of 1 M LiALH₄ (11 ml, 11 mmol) in dry THF under argonatmosphere. The mixture was refluxed for 4 hours. A solution ofsaturated sodium tartrate (20 ml) was added to the crude and the mixtureis stirred for 1 hour. Then, extracted with ethyl acetate (3×20 ml),dried over Na₂SO₄, filtered and evaporated to dryness to afford an oil(304 mg, 90% yield), which is precipitate with a solution of 2.8 NHCl/EtOH and ethyl acetate, to affordEthyl-[3-(7,8-Dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-aminedihydrochloride (333 mg, 80% yield).

¹H NMR (300 MHz, DMSO-D6) 8 ppm 1.20 (t, J=7.10 Hz, 3H) 2.13 (m, 3H)2.61 (m, 1H) 2.93 (m, 8H) 3.17 (m, 2H) 3.48 (m, 1H) 3.73 (s, 3H) 3.75(s, 3H) 3.79 (m; 1H) 4.50 (q, J=9.08 Hz, 1H) 6.77 (s, 1H) 9.12 (br, 2H)10.72 (br, 1H)

MS (APCI (M+H)⁺): 305

Example G

This is an example of a compound of general Formula (IV) from a compoundof general Formula (Va).

3-(3-Amino-propyl)-2a,3,4,5-tetrahydro-2H-3-aza-acenaphthylen-1-one a)[4-(7,8-Dimethoxy-1-oxo-2,2a,4,5-tetrahydro-H-3-aza-acenaphthylen-3-yl)-butyl]-carbamicacid tert-butyl ester

Over a suspension of7,8-Dimethoxy-2a,3,4,5-tetrahydro-2H-3-aza-acenaphthylen-1-one (0.950 g,4.1 mmol), K₂CO₃ (1.89 g, 13.6 mmol) and NaI (0.061 g, 0.4 mmol) in DMF(20 ml) is slowed added (4-Bromo-butyl)-carbamic acid tert-butyl ester(1.09 g, 4.32 mmol) and the mixture is strirred overnight. Then, water(40 ml) and ethyl acetate (40 ml) are added and the layers areseparated. The aqueous phase is extracted with ethyl acetate (2×40 ml).The organic layers are collected and washed with water (3×40 ml). Afterdrying with Na₂SO₄, filtration and vacuum concentration, a brown oil isobtained, which is purified by silicagel chromatography using a gradientof CH₂Cl₂/methanol (from 100% to 98% CH₂Cl₂) to obtain a brown solid(0.730 g, 45% yield)

¹H NMR (300 MHz, DMSO-D6) 8 ppm 1.41 (s, 9H) 1.58 (m, 3H) 2.41 (m, 2H)2.68 (m, 2H) 2.92 (m, 3H) 3.14 (m, 2H) 3.38 (m, 1H) 3.58 (m, 1H) 3.85(s, 3H) 4.04 (s, 3H) 4.84 (m, 1H) 6.92 (s, 1H)

MS (APCI (M+H)⁺): 405

b)3-(4-Amino-butyl)-7,8-dimethoxy-2a,3,4,5-tetrahydro-2H-3-aza-acenaphthylen-1-onedihydro-chloride

[4-(7,8-Dimethoxy-1-oxo-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-carbamicacid tert-butyl ester (498 mg, 1.22 mmol) is dissolved in a mixture ofCH₂Cl₂ (10 ml) and ethanol (2 ml) and a solution of 2 N HCl in Et₂O isadded (6 ml, 12 mmol). A brown precipitate appears, which is collectedby filtration (367 mg, 80% yield).

¹H NMR (300 MHz, DMSO-D6) δ ppm 1.61 (m, 2H) 1.87 (m, 2H) 2.81 (m, 2H)3.10 (m, 6H) 3.48 (m, 2H) 3.82 (s, 3H) 3.87 (s, 3H) 4.75 (m, 1H) 7.30(s, 1H) 8.02 (s, 3H) 11.33 (br, 1H)

MS (APCI (M+H)⁺): 305

Example H 2,3-Dihydro-benzofuran-5-sulfonic acid[3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amidehydrochloride (28)

2,3-Dihydro-benzofuran-5-sulfonyl chloride (24.05 mg, 0.11 mmol) wasadded to a solution of3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propylaminedihydro-chloride (28.92 mg, 0.1 mmol) and N,N′-diisopropylethylamine(51.7 mg, 0.4 mmol) in CH₂Cl₂ (10 mL) and the mixture was stirredovernight at room temperature. The resulting solution was washed withwater (3×10 mL), dried over Na₂SO₄ and evaporated to dryness. The freebase was dissolved in ethyl acetate (1 ml). A 2.8 M solution of hydrogenchloride in ethanol (0.10 mL) was then added. The product wascrystallized and collected by filtration, and vacuum dried to give awhite solid (33 mg, 77%).

¹H NMR (300 MHz, DMSO-D6) δ ppm 1.92 (m, 4H) 2.56 (m, 1H) 2.83 (m, 4H)3.09 (m, 3H) 3.24 (m, 2H) 3.39 (m, 1H) 3.77 (d, J=11.13 Hz, 1H) 4.62 (m,3H) 6.93 (d, J=8.49 Hz, 1H) 7.08 (d, J=7.47 Hz, 1H) 7.17 (m, 1H) 7.26(t, J=7.47 Hz, 1H) 7.60 (m, 3H) 10.27 (br, 1H)

MS (APCI (M+H)⁺): 399

Example IN-[3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-m-tolyl-benzene-sulfonamidehydrochloride (97)

Benzenesulfonyl chloride (48.6 mg, 0.28 mmol) was added to a solution of[3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-m-tolyl-aminedihydro-chloride (43.0 mg, 0.11 mmol) and N,N′-diisopropylethylamine (2ml) in CH₂Cl₂ (2 mL) and the mixture was stirred overnight at roomtemperature. The resulting solution was washed with water (3×10 ml),dried over Na₂SO₄ and evaporated to dryness. The free base was dissolvedin ethyl acetate (1 ml). A 2.8 M solution of hydrogen chloride inethanol (0.10 mL) was then added. The product was crystallized andcollected by filtration, and vacuum dried to give a white solid (20.0mg, 36% yield).

¹H NMR (300 MHz, DMSO-D6) δ ppm 1.89 (m, 3H) 2.27 (s, 3H) 2.56 (m, 1H)2.90 (d, J=7.18 Hz, 2H) 3.08 (m, 2H) 3.20 (td, J=11.94, 5.71 Hz, 1H)3.41 (m, 2H) 3.69 (m, 2H) 3.76 (m, 1H) 4.62 (q, J=9.52 Hz, 1H) 6.86 (d,J=7.76 Hz, 1H) 6.94 (s, 1H) 7.08 (d, J=7.47 Hz, 1H) 7.17 (m, 2H) 7.27(t, J=7.62 Hz, 2H) 7.59 (m, 4H) 7.73 (t, J=6.88 Hz, 1H) 10.24 (br, 1H)

MS (APCI (M+H)⁺): 447

Example JN-Ethyl-4-methyl-N-[3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamidehydrochloride (89)

4-Methylbenzenesulfonyl chloride (20.9 mg, 0.11 mmol) was added to asolution of Ethyl-[3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amine dihydrochloride (31.7 mg, 0.1 mmol) andN,N′-diisopropylethylamine (64.6 mg, 0.5 mmol) in CH₂Cl₂ (10 mL) and themixture was stirred overnight at room temperature. The resultingsolution was washed with water (3×10 mL), dried over Na₂SO₄ andevaporated to dryness. The free base was dissolved in ethyl acetate (1ml). A 2.8 M solution of hydrogen chloride in ethanol (0.10 mL) was thenadded. The product was crystallized and collected by filtration, andvacuum dried to give a white solid (18.0 mg, 41%).

¹H NMR (300 MHz, DMSO-D6) δ ppm 1.02 (t, J=7.10 Hz, 3H) 2.04 (m, 4H)2.38 (s, 3H) 2.58 (m, 1H) 2.89 (m, 2H) 3.12 (m, 5H) 3.17 (q, J=7.18 Hz,2H) 3.42 (m, 1H) 3.85 (d, J=10.99 Hz, 1H) 4.63 (q, J=9.52 Hz, 1H) 7.09(d, J=7.47 Hz, 1H) 7.17 (m, 1H) 7.27 (t, J=7.47 Hz, 1H) 7.42 (d, J=8.06Hz, 2H) 7.69 (d, J=8.06 Hz, 2H) 10.36 (br, 1H)

MS (APCI (M+H)⁺): 399

Example K2-Chloro-N-[3-(7,8-dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-ethyl-benzenesulfonamidehydrochloride (111)

2-Chlorobenzenesulfonyl chloride (246.1 mg, 1.17 mmol) was added to asolution ofEthyl-[3-(7,8-Dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-aminedihydro-chloride (400 mg, 1.06 mmol) and N,N′-diisopropylethylamine(1.01 ml, 6.4 mmol) in CH₂Cl₂ (20 mL) and the mixture was stirredovernight at room temperature. The resulting solution was washed withwater (3×20 mL), dried over Na₂SO₄ and evaporated to dryness. The freebase was dissolved in ethyl acetate and A 2.8 M solution of hydrogenchloride in ethanol (0.50 mL) was then added. The product wascrystallized and collected by filtration, and vacuum dried to give awhite solid (233 mg, 43%).

¹H NMR (300 MHz, DMSO-D6) δ ppm 1.00 (t, J=6.96 Hz, 3H) 2.02 (m, 4H)2.54 (m, 1H) 2.88 (m, 2H) 3.03 (m, 4H) 3.29 (q, J=6.96 Hz, 2H) 3.43 (m,2H) 3.72 (s, 3H) 3.75 (s, 3H) 3.78 (m, 1H) 4.51 (q, J=9.33 Hz, 1H) 6.78(s, 1H) 7.56 (m, 1H) 7.68 (qd, J=8.01, 1.46 Hz, 2H) 7.98 (m, 1H) 10.24(br, 1H).

MS (APCI (M+H)⁺): 479

Example L2-Chloro-N-[4-(7,8-dimethoxy-oxo-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamidehydrochloride (127)

2-Chlorobenzenesulfonyl chloride (92.4 mg, 0.44 mmol) was added to asolution of3-(4-Amino-butyl)-7,8-dimethoxy-2a,3,4,5-tetrahydro-2H-3-aza-acenaphthylen-1′-onedihydro-chloride (150 mg, 0.40 mmol) and N,N′-diisopropylethylamine(0.400 ml) in CH₂Cl₂ (20 mL) and the mixture was stirred overnight atroom temperature. The resulting solution was washed with water (3×20mL), dried over Na₂SO₄ and evaporated to dryness. The free base wasdissolved in ethyl acetate (2 ml) and A 2.8 M solution of hydrogenchloride in ethanol was then added. The product was crystallized andcollected by filtration, and vacuum dried to give a pale brown solid(135 mg, 66%).

¹H NMR (300 MHz, DMSO-D6) δ ppm 1.47 (m, 2H) 1.73 (m, 2H) 2.86 (m, 2H)3.10 (m, 6H) 3.45 (m, 2H) 3.82 (s, 3H) 3.87 (s, 3H) 4.72 (m, 1H) 7.30(s, 1H) 7.54 (m, 1H) 7.66 (m, 2H) 7.98 (m, 2H) 10.80 (br, 1H)

MS (APCI (M+H)⁺): 479

The spectroscopic data for the identification of some of the sulfonamidecompounds of the invention having general formula (I), preparedanalogously to the methods described in the above examples, are shown inthe following table 1:

N^(o) STRUCTURE Autonom 1

2-Chloro-N-[4-(2,2a-4,5-tetrahydro- 1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 2

2,5-Dichloro-N-[4-(2,2a,4,5-tetrahy- dro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide 3

N-[4-(2,2a,4-5-Tetrahydro-1H-3-aza- acenaphthylen-3-yl)-butyl]-benzenesulfonamide 4

Quinoline-8-sulfonic acid[4-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-butyl]-amide trifluoroacetate 5

3-Methyl-N-[4-(2,2a,4-5-tetrahydro- 1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide trifluoroacetate 6

2-Chloro-4,5-difluoro-N-[4-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-butyl]-benzenesulfonamidehydrochloride 7

4-Chloro-2,5-dimethyl-N-[4-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-butyl]-benzenesulfonamidehydrochloride 8

3-Chloro-4-fluoro-N-[4-(2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 9

2,4,5-Trichloro-N-[4-(2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 10

5-fluoro-2-methyl-N-[4-(2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 11

Naphthalene-1-sulfonic acid[4-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-butyl]-amide 12

Thiophene-2-sulfonic acid[4-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-butyl]-amide 13

5-Chloro-2,4-difluoro-N-[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl]-benzenesulfonamidehydrochloride 14

2-Chloro-N-[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]- benzenesulfonamide hydrochloride15

2,5-Dichloro-N-[3-(2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 16

N-[3-(2,2a,4-5-tetrahydro-1H-3-aza- acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 17

2-Chloro-4,5-difluoro-N-[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl]-benzenesulfonamidehydrochloride 18

4-Chloro-2,5-dimethyl-N-[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl]-benzenesulfonamidehydrochloride 19

3-Chloro-4-fluoro-N-[3-(2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 20

Quinoline-8-sulfonic acid[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl]-amide 21

3-Methyl-N-[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]- benzenesulfonamide hydrochloride22

2,4,5-Trichloro-N-[3-(2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide 23

5-Fluoro-2-methyl-N-[3-(2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 24

Naphthalene-1-sulfonic acid[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-propyl]-amide 25

Thiophene-2-sulfonic acid[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylene-3- yl)-propyl]-amide hydrochloride 26

4-Fluoro-naphthalene-1-sulfonic acid[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylene-3-yl)-propyl]-amide hydrochloride 27

Biphenyl-2-sulfonic acid[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl]-amide hydrochoride 28

2,3-Dihydro-benzofuran-5-sulfonic acid[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amide hydrochloride 29

Dibenzofuran-2-sulfonic acid[3- (2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amide hydrochloride 30

2-Methoxy-4-methyl-N-[3-(2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 31

5-Isoxazol-5-yl-thiophen-2-sulfonicacid[3-(2,2a,4-5-tetrahydro-1H-3-aza- acenaphthylen-3-yl)-propyl]-amidehydrochloride 32

4-Fluoro-naphthalene-1-sulfonic acid[4-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylene-3-yl)-butyl]-amide 33

Biphenyl-2-sulfonic acid[4-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-butyl]-amide hydrochloride 34

2,3-Dihydro-benzofuran-5-sulfonic acid[4-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-amide hydrochloride 35

Dibenzofuran-2-sulfonic acid[4- (2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-amide hydrochloride 36

2-Methoxy-4-methyl-N-[4-(2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 37

5-Isoxazol-5-yl-thiophene-2-sulfonicacid[4-(2,2a,4-5-tetrahydro-1H-3-aza- acenaphthylen-3-yl)-butyl]-amidehydrochloride 38

4-Chloro-naphthalene-1-sulfonic acid[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-amide 39

2-Bromo-N-[3-(2,2a,4-5-tetrahydro- 1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide 40

4-Chloro-naphthelene-1-sulfonic acid[3-(2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amide 41

5-Chloro-N-[4-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-butyl]-2,4-difluoro-benzenesulfonamide hydrochloride 42

2-Chloro-N-[4-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-butyl]-benzenesulfonamidehydrochloride 43

2,5-Dichloro-N-[4-(7,8-dimethoxy- 2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]- benzenesulfonamide hydrochloride 44

N-[4-(7,8-dimethoxy-2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 45

2-Chloro-N-[4-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-butyl]-4,5-difluoro-benzenesulfonamide hydrochloride 46

4-Chloro-N-[4-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-butyl]-2,5-dimethyl-benzenesulfonamide hydrochloride 47

3-Chloro-N-[4-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-butyl]-4-fluoro-benzenesulfonamide hydrochloride 48

2-Bromo-N-{4-(7,8-dimethoxy-2,2a,4- 5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzene sulfonamide hydrochloride 49

N-[4-(7,8-dimethoxy-2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-3-methyl-benzene sulfonamide hydrochloride 50

2,4,5-Trichloro-N-[4-(7,8-dimethoxy- 2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzene sulfonamide hydrochloride 51

N-[4-(7,8-dimethoxy-2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-5-fluoro-2-methyl-benzene sulfonamide hydrochloride 52

Naphtalene-1-sulfonic acid [4-(7,8- dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-amide hydrochloride 53

Thiophene-2-sulfonic acid [4-(7,8- dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-amide hydrochloride 54

5-Chloro-N-[3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-propyl]-2,4-difluoro-benzenesulfonamide hydrochloride 55

2-Chloro-N-[3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-propyl]-benzene sulfonamidehydrochloride 56

2,5-Dichloro-N-[3-(7,8-dimethoxy- 2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzene sulfonamide hydrochloride 57

N-[3-(7,8-dimethoxy-2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzene sulfonamide hydrochloride 58

2-Chloro-N-[3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-propyl]-4,5-difluoro-benzenesulfonamide hydrochloride 59

4-Chloro-N-[3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-propyl]-2,5-dimethyl-benzenesulfonamide hydrochloride 60

3-Chloro-N-[3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-propyl]-4-fluoro-benzenesulfonamide hydrochloride 61

2-Bromo-N-[3-(7,8-dimethoxy-2,2a,4- 5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzene sulfonamide hydrochloride 62

N-[3-(7,8-dimethoxy-2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-3-methyl-benzene sulfonamide hydrochloride 63

2,4,5-Trichloro-N-[3-(7,8-dimethoxy- 2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzene sulfonamide hydrochloride 64

N-[3-(7,8-dimethoxy-2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-5-fluoro-2-methyl-benzene sulfonamide hydrochloride 65

Naphtalene-1-sulfonic acid [3-(7,8- dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amide hydrochloride 66

Thiophene-2-sulfonic acid [3-(7,8- dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amide hydrochloride 67

4-Fluoro-naphtalene-1-sulfonic acid [3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]- amide 68

Biphenyl-2-sulfonic acid[3-(7,8- dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amide 69

2,3-Dihydro-benzofuran-5-sulfonic acid[3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl}-amide 70

Dibenzofuran-2-sulfonic acid[3-(7,8- dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amide hydrochloride 71

N-[3-(7,8-Dimethoxy-2,2a,4-5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-2-methoxy-4-methyl- benzenesulfonamide 72

5-Isoxazol-5-yl-thiophene-2-sulfonic acid[3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl]-amide hydrochloride 73

4-Chloro-naphtalene-1-sulfonic acid [3-(7,8-dimethoxy-2,2a,4-5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amide 74

5-CHloro-2,4-difluoro-N-[4-(2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]benzenesulfonamide hydrochloride 75

4-Chloro-N-ethyl-2,5-dimethyl-N-[3- (2,2a,4,5-tetrahydro-1H-3-aza-acena-phthylen-3-yl)-propyl]benzenesulfo- Namide hydrochloride 76

4-Chloro-N-ethyl-N-[3-(7-methoxy- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-2,5- dimethyl-benzenesulfonamidehydrochloride 77

4-Chloro-N-[3-(7,8-dimethoxy- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-ethyl- 2,5-dimethyl-benzenesulfonamidehydrochloride 78

2,3-Dihydro-benzofuran-5-sulfonic acid ethyl-[3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]- amide hydrochloride 79

2,3-Dihydro-benzofuran-5-sulfonic acid [3-(7,8-dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl]-ethylamidehydrochloride 80

2,5-Dichloro-N-[3-(7,8-dimethoxy- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-ethyl- benzene sulfonamide hydrochloride81

2,3-Dihydro-benzofuran-5-sulfonic acid [3-(7,8-dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl)-m-tolyl-amidehydrochloride 82

2,3-Dihydro-benzofuran-5-sulfonic acid [3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-m- tolyl-amide hydrochloride 83

2,5-Dichloro-N-[3-(2,2a,4,5-tetrahydro- 1H-3-aza-acenaphthylen-3-yl)-propyl]-N-m-tolyl-benzenesulfonamide hydrochloride 84

2,5-Dichloro-N-[3-(7,8-dimethoxy- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-m-tolyl- benzenesulfonamide hydrochloride85

4-Chloro-2,5-dimethyl-N-[3-(1-oxo- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]- benzenesulfonamide hydrochloride 86

2,3-Dihydro-benzofuran-5-suflonic acid [3-(1-oxo-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]- amide hydrochloride 87

Naphthalene-1-sulfonic acid ethyl- [3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amide hydrochloride 88

N-Ethyl-3-methyl-N-[3-(2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 89

N-Ethyl-4-methyl-N-[3-(2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 90

N-Ethyl-2,5-dimethoxy-N-[3-(2,2a,4, 5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 91

4-Methyl-N-[3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]- N-m-tolyl-benzenesulfonamidehydrochloride 92

4-Chloro-2,5-dimethyl-N-[3-(2,2a,4, 5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-m-tolyl-benzenesul- fonamide hydrochloride 93

2-Chloro-N-ethyl-N-[3-(2,2a,4,5-tetra-hydro-1H-3-aza-acenaphthylen-3-yl)- propyl]-benzenesulfonamidehydrochloride 94

N-Ethyl-N-[3-(2,2a,4,5-tetrahydro-1H- 3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 95

2,5-Dichloro-N-ethyl-N-[3-(2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 96

Quinoline-8-sulfonic acid ethyl-[3- (2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-amide hydrochloride 97

N-[3-(2,2a,4,5-Tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-m-tolyl- benzenesulfonamide hydrochloride98

N-Ethyl-4-methyl-N-[4-(2,2a,4,5-tetra-hydro-1H-3-aza-acenaphthylen-3-yl)- butyl]-benzenesulfonamidehydrochloride 99

2-Chloro-N-ethyl-N-[4-(2,2a,4,5-tetra-hydro-1H-3-aza-acenaphthylen-3-yl)- butyl]-benzenesulfonamidehydrochloride 100

2,5-Dichloro-N-ethyl-N-[4-(2,2,a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 101

N-Ethyl-N-[4-(2,2a,4,5-tetrahydro-1H- 3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 102

N-Ethyl-3-methyl-N-[4-(2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 103

4-Chloro-N-ethyl-2,5-dimethyl-N-[4- (2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]- benzenesulfonamide hydrochloride 104

Quinoline-8-sulfonic acid ethyl-[4- (2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-amide hydrochloride 105

Naphthalene-1-sulfonic acid ethyl-[4- (2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-amide hydrochloride 106

N-[3-(7,8-Dimethoxy-2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-ethyl-4-methyl- benzenesulfonamide hydrochloride 107

N-[3-(7,8-Dimethoxy-2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-ethyl- benzenesulfonamide hydrochloride 108

N-[3-(7,8-Dimethoxy-2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-ethyl-3-methyl- benzenesulfonamide hydrochloride 109

Naphthalene-1-sulfonic acid [3-(7,8- dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-ethyl- amide hydrochloride 110

4-Chloro-N-[4-(7,8-dimethoxy- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-N-ethyl- 2,5-dimethyl-benzenesulfonamidehydrochloride 111

2-Chloro-N-[3-(7,8-dimethoxy- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-ethyl- benzenesulfonamide hydrochloride112

2,5-Dichloro-N-[4-(7,8-dimethoxy- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-N-ethyl- benzenesulfonamide hydrochloride 113

N-[4-(7,8-Dimethoxy-2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-N-ethyl-benzenesulfonamide hydrochloride 114

N-[4-(7,8-Dimethoxy-2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-N-ethyl-3-methyl- benzenesulfonamide hydrochloride 115

Naphthalene-1-sulfonic acid [4-(7,8- dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-ethyl- amide hydrochloride 116

2-Chloro-N-[4-(7,8-dimethoxy- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-N-ethyl- benzenesulfonamide hydrochloride 117

N-[4-(7,8-Dimethoxy-2,2a,4,5-tetrahy- dro-1H-3-aza-acenaphthylen-3-yl)-butyl]-N-ethyl-4-methyl- benzenesulfonamide hydrochloride 118

Quinolin-8-sulfonic acid [4-(7,8- dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-ethyl- amide hydrochloride 119

N-[4-(7,8-Dimethoxy-2,2a,4,5- tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-4-methyl- benzenesulfonamide hydrochloride 120

Quinoline-8-sulfonic acid [3-(7,8- dimethoxy-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-ethyl- amide hydrochloride 121

4-Chloro-N-[4-(7,8-dimethoxy-1-oxo- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-2,5- dimethyl-benzenesulfonamidehydrochloride 122

4-Chloro-N-[4-(7,8-dimethoxy-1-oxo-2,2a,4,5-tetrahydro-1H-3-aza-acenaph- thylen-3-yl)-butyl]-N-ethyl-2,5-dimethyl-benzenesulfonamide hydrochloride 123

2-Chloro-N-[3-(1-oxo-2,2a,4,5-tetra hydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 124

2-Chloro-N-ethyl-N-[3-(1-oxo-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-propyl]-benzenesulfonamidehydrochloride 125

2-Chloro-N-[3-(7,8-dimethoxy-1-oxo-2,2a,4,5-tetrahydro-1H-3-aza-acenaph- thylen-3-yl)-propyl]-benzenesulfonamide hydrochloride 126

2-Chloro-N-[3-(7,8-dimethoxy-1-oxo-2,2a,4,5-tetrahydro-1H-3-aza-acenaph- thylen-3-yl)-propyl]-N-ethyl-benzenesulfonamide hydrochloride 127

2-Chloro-N-[4-(7,8-dimethoxy-1-oxo-2,2a,4,5-tetrahydro-1H-3-aza-acenaph- thylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 128

2-Chloro-N-[4-(7,8-dimethoxy-1-oxo-2,2a,4,5-tetrahydro-1H-3-aza-acenaph- thylen-3-yl)-butyl]-N-ethyl-benzenesulfonamide hydrochloride 129

2-Chloro-N-[4-(1-oxo-2,2a,4,5-tetra hydro-1H-3-aza-acenaphthylen-3-yl)-butyl]-benzenesulfonamide hydrochloride 130

2-Chloro-N-ethyl-N-[4-(1-oxo-2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen- 3-yl)-butyl]-benzenesulfonamidehydrochloride 131

(S)-2-Chloro-N-[3-(7,8-dimethoxy- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-ethyl- benzenesulfonamide hydrochloride132

(R)-2-Chloro-N-[3-(7,8-dimethoxy- 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3-yl)-propyl]-N-ethyl- benzenesulfonamide hydrochloride133

(S)-N-Ethyl-4-methyl-N-[3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl]-benzenesulfonamidehydrochloride 134

(R)-N-Ethyl-4-methyl-N-[3-(2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen-3- yl)-propyl]-benzenesulfonamidehydrochloride 135

(S)-Naphthalen-1-sulfonic acid ethyl-[3-(2,2a,4,5-tetrahydro-1H-3-aza-ace naphthylen-3-yl)-propyl]-amidehydrochloride 136

(R)-Naphthalene-1-sulfonic acid ethyl-[3-(2,2a,4,5-tetrahydro-1H-3-aza-ace naphthylen-3-yl)-propyl]-amidehydrochloride MS (APCI) N^(o) ¹H-NMR (M + H)⁺) 1 405 2 1H NMR (400 MHz,DMSO-D6) δ 439 ppm 1.41(m, 5 H) 2.04(m, 1 H) 2.15 (m, 1 H) 2.30(m ,1 H)2.54(m, 1 H) 2.70(m, 3 H) 2.76(m, 1 H) 2.88(s, 2 H) 3.08(m, 1 H) 3.24(m,1 H) 6.87 (d, J = 7.23 Hz, 1 H) 7.00(m, 2 H) 7.65(m, 2 H) 7.87(d, J =1.86 Hz, 1 H) 8.12(s, 1 H) 3 371 4 422 5 385 6 441 7 1H NMR (300 MHz,DMSO-D6) δ 433 ppm 1.25(m, 1 H) 1.47(m, 2 H) 1.70 (m, 2 H) 1.98(m, 1 H)2.34(s, 3 H) 2.51(s, 3 H) 2.60(m, 1 H) 2.79(q, J = 6.64 Hz, 2 H) 2.88(d,J = 9.67 Hz, 2 H) 3.09(m, 3 H) 3.39(m, 1 H) 3.77(d, J = 9.96 Hz, 1 H)4.55(m, 1 H) 7.08(d, J = 7.18 Hz, 1 H) 7.16(d, J = 7.03 Hz, 1 h) 7.26(t,J = 7.54 Hz, 1 H) 7.51(s, 1 H) 7.76(s, 1 H) 7.81(t, J = 5.86 Hz, 1 H)10.16(br, 1 H) 8 423 9 473 10 403 11 421 12 377 13 ¹H NMR (300 MHz,DMSO-D60 δ 427 ppm 1.97(m, 4 H) 2.57(m, 1 H) 2.88 (m, 2 H) 3.00(q, J =6.35 Hz, 2 H) 3.10(m, 3 H) 3.40(m, 1 H) 3.78(m, 1 H) 4.59(m, 1 H)7.08(d, J = 7.47 Hz, 1 H) 7.16(m, 1 H) 7.25(m, 1 H) 7.92(m, 2 H) 8.36(t,J = 5.78 Hz, 1 H) 10.26(br, 1 H) 14 391 15 425 16 357 17 427 18 419 19409 20 408 21 371 22 459 23 389 24 407 25 363 26 425 27 433 28 1H NMR(300 MHz, DMSO-D6) δ 399 ppm 1.92(m, 4 H) 2.56(m, 1 H) 2.83 (m, 4 H)3.09(m, 3 H) 3.24(m, 2 H) 3.39(m, 1 H) 3.77(d, J = 11.13 Hz, 1 H)4.62(m, 3 H) 6.93(d, J = 8.49 Hz, 1 H) 7.08(d, J = 7.47 Hz, 1 H) 7.17(m, 1 H) 7.26(t, J = 7.47 Hz, 1 H) 7.60(m, 3 H) 10.27(br, 1 H) 29 447 30401 31 1H NMR (300 MHz, DMSO-D6) δ 430 ppm 1.95(m, 3 H) 2.56(m, 1 H)2.86 (m, 2 H) 3.02(m, 2 H) 3.11(m, 3 H) 3.41(m, 2 H) 3.80(d, J = 10.74Hz, 1 H) 4.60(m, 1 H) 7.12(m, 3 H) 7.26 (t, J = 7.45 Hz, 1 H) 7.71(d, J= 3.91 Hz, 1 H) 7.78(d, J = 3.91 Hz, 1 H) 8.34(t, J = 5.74 Hz, 1 H)8.74(d, J = 1.95 Hz, 1 H) 10.31(br, 1 H) 32 439 33 447 34 413 35 461 36415 37 ¹H NMR (300 MHz, DMSO-D6) δ 444 ppm 1.51(m, 2 H) 1.72(m, 2 H)1.99 (m, 1 H) 2.63(m, 1 H) 2.88(m, 4 H) 3.08(m, 3 H) 3.39(m, 2 H)3.81(m, 1 H) 4.54(m, 1 H) 7.09(m, 2 H) 7.16(d, J = 7.82 Hz, 1 H) 7.26(t,J = 7.47 Hz, 1 H) 7.69(d, J = 3.95 Hz, 1 H) 7.76(d, J = 3.95 Hz, 1 H)8.20(t, J = 5.71 Hz, 1 H) 8.73(d, J = 2.05 Hz, 1 H) 10.18(br, 1 H) 38455 39 435 40 441 41 501 42 465 43 499 44 431 45 501 46 493 47 483 48509 49 445 50 533 51 463 52 481 53 437 54 487 55 451 56 485 57 ¹H NMR(300 MHz, DMSO-D6) δ 417 ppm 1.89(m, 4 H) 2.54(m, 1 H) 2.84 (m, 3 H)3.00(m, 4 H) 3.41(m, 1 H) 3.71(m, 1 H) 3.72(s, 3 H) 3.75(s, 3 H) 4.49(m,1 H) 6.77(s, 1 H) 7.63 (m, 3 H) 7.80(m, 3 H) 10.05(br, 1 H) 58 ¹H NMR(300 MHz, DMSO-D6) δ 487 ppm 1.96(s, 4 H) 2.58(m, 1 H) 2.87 (m, 3 H)2.99(m, 4 H) 3.40(m, 1 H) 3.72(s, 3 H) 3.74(s, 3 H) 3.75(m, 1 H) 4.49(d,J = 5.86 Hz, 1 H) 6.77(s, 1 H) 8.01(m, 2 H) 8.31(t, J = 5.49 Hz, 1 H)10.20(br, 1 H) 59 481 60 469 61 495 62 431 63 521 64 449 65 467 66 42367 485 68 493 69 459 70 507 71 461 72 490 73 501 74 441 75 447 76 477 77507 78 427 79 487 80 1H NMR (300 MHz, DMSO-d₆) δ 513 ppm 1.03(t, J =7.03 Hz, 3 H) 1.99 (m, 4 H) 2.54(m, 1 H) 2.88(m, 2 H) 3.03(m, 4 H)3.36(q, J = 7.03 Hz, 2 H) 3.44(m, 2 H) 3.73(s, 3 H) 3.75(s, 3 H) 3.79(m,1 H) 4.51(q, J = 9.37 Hz, 1 H) 6.78(s, 1 H) 7.77(td, J = 8.17, 5.35 Hz,2 H) 7.96(d, J = 1.90 Hz, 1 H) 10.23(br, 1 H) 81 549 82 489 83 515 84575 85 433 86 413 87 1H NMR (300 MHz, DMSO-d₆) δ 435 ppm 1.01(t, J = 6.9Hz, 3 H) 2.01 (m, 4 H) 2.41(m, 1 H) 2.87(d, J = 8.64 Hz, 2 H) 3.05(m, 3H) 3.39 (m, 5 H) 3.80(m, 1 H) 4.519m, 1 H) 7.08(d, J = 7.32 Hz, 1 H)7.16(m, 1 H) 7.27(t, J = 7.18 Hz, 1 H) 7.70(m, 3 H) 8.12(d, J = 8.35 Hz,2 H) 8.27 (d, J = 7.91 Hz, 1 H) 8.54(d, J = 8.64 Hz, 1 H) 10.25(br, 1 H)88 1H NMR (300 MHz, DMSO-d₆) δ 399 ppm 1.03(t, J = 6.9 Hz, 3 H) 2.04 (m,4 H) 2.40(s, 3 H) 2.58(m, 1 H) 2.90(d, J = 7.91 Hz, 2 H) 3.16(m, 6 H)3.42(m, 2 H) 3.85(d, J = 11.86 Hz, 1 H) 4.63(q, J = 9.28 Hz, 1 H)7.09(d, J = 7.47 Hz, 1 H) 7.17(m, 1 H) 7.27(t, J = 7.40 Hz, 1 H) 7.50(d,J = 4.83 Hz, 2 H) 7.60(m, 2 H) 10.40 (br, 1 H) 89 1H NMR (300 MHz,DMSO-d₆) δ 399 ppm 1.02(t, J = 7.10 Hz, 3 H) 2.04 (m, 4 H) 2.38(s, 3 H)2.58(m, 1 H) 2.89(m, 2 H) 3.12(m, 5 H) 3.17(q, J = 7.18 Hz, 2 H) 3.42(m,1 H) 3.85 (d, J = 10.99 Hz, 1 H) 4.63(q, J = 9.52 Hz, 1 H) 7.09(d, J =7.47 Hz, 1 H) 7.17(m, 1 H) 7.27(t, J = 7.47 Hz, 1 H) 7.42(d, J = 8.06Hz, 2 H) 7.69(d, J = 8.06 Hz, 2 H) 10.36(br, 1 H) 90 445 91 461 92 50993 419 94 385 95 453 96 436 97 447 98 413 99 433 100 467 101 399 102 413103 461 104 450 105 449 106 459 107 445 108 459 109 495 110 521 111 1HNMR (300 MHz, DMSO-d₆) δ 479 ppm 1.00(t, J = 6.9 Hz, 3 H) 2.02 (m, 4 H)2.54(m, 1 H) 2.88(m, 2 H) 3.03(m, 4 H) 3.29(q, J = 6.9 Hz, 2 H) 3.43(m,2 H) 3.72(s, 3 H) 3.75 (s, 3 H) 3.78(m, 1 H) 4.51(q, J = 9.33 Hz, 1 H)6.78(s, 1 H) 7.56(m, 1 H) 7.68(qd, J = 8.01, 1.46 Hz, 2 H) 7.98 (m, 1 H)10.24(br, 1H) 112 527 113 459 114 473 115 509 116 493 117 473 118 510119 445 120 496 121 1H NMR (300 MHz, DMSO-d₆) δ 507 ppm 1.44(m, 2 H)1.70(m, 2 H) 2.34 (s, 3 H) 2.51(s, 3 H) 2.78(m, 2 H) 3.07(m, 6 H)3.43(m, 2 H) 3.82(s, 3 H) 3.87(s, 3 H) 4.72(m, 1 H) 7.30 (s, 1 H)7.51(s, 1 H) 7.76(s, 1 H) 7.82(m, 1 H) 10.66(br, 1 H) 122 535 123 405124 433 125 465 126 493 127 1H NMR (300 MHz, DMSO-d₆) δ 479 ppm 1.47(m,2 H) 1.73(m, 2 H) 2.86 (m, 2 H) 3.10(m, 6 H) 3.45(m, 2 H) 3.82(s, 3 H)3.87(s, 3 H) 4.73(m, 1 H) 7.30(s, 1 H) 7.54(m, 1 H) 7.66 (m, 2 H)7.98(m, 2 H) 10.80(br, 1 H) 128 507 129 419 130 447 131 479 132 479 133399 134 399 135 435 136 435

Biological Assays Radioligand Binding

Radioligand binding assays were performed using the Cloned HumanSerotonin Receptor, Subtype 7 (h5HT₇), expressed in CHO cells, coated onFlashplate (Basic FlashPlate Cat.: SMP200) from PerkinElmer (Cat.:6120512). The protocol assay was essentially the recommended protocol inthe Technical Data Sheet by PerkinEmer Life and Analytical Sciences. TheMass membrane protein/well was typically 12 fig and the Receptor/wellwas about 9-10 fmoles. The Flashplate were let equilibrate at roomtemperature for one hour before the addition of the components of theassay mixture. The binding buffer was: 50 mM Tris-HCl, pH 7.4,containing 10 mM MgCl₂, 0.5 mM EDTA and 0.5% BSA. The radioligand was[¹²⁵I]LSD at a final concentration of 0.82 nM. Nonspecific binding wasdetermined with 50 μM of Clozapine. The assay volume was 25 μl.TopSeal-A were applied onto Flashplate microplates and they wereincubated at room temperature for 240 minutes in darkness. Theradioactivity were quantified by liquid scintillation spectrophotometry(Wallac 1450 Microbeta Trilux) with a count delay of 4 minutes prior tocounting and a counting time of 30 seconds per well. Competition bindingdata were analyzed by using the LIGAND program (Munson and Rodbard,LIGAND: A versatile, computerized approach for characterization ofligand-binding systems. Anal. Biochem. 107: 220-239, 1980) and assayswere performed in triplicate determinations for each point. Results forrepresentative compounds are given in the table 2 below:

TABLE 2 COMPOUND 5-HT7 IC-50 (nM) 7 79.2 15 142.1 56 155.6 58 188.5 806.2 87 20.3 88 4.5 89 6.7 111 8.0

1. A method of treating or preventing a 5-HT₇ mediated disease orcondition comprising, administering a composition containing formula I:

wherein W is a substituted or unsubstituted alkyl, substituted orunsubstituted alkenyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted aryl, substituted or unsubstitutedheterocyclyl; R¹, R², R³, R⁴, R^(4B), R⁵, R^(5B), R⁶ and R⁷ are eachindependently selected from the group formed by hydrogen, substituted orunsubstituted alkyl, substituted or unsubstituted cycloalkyl,substituted or unsubstituted alkenyl, substituted or unsubstituted aryl,substituted or unsubstituted heterocyclyl, —COR⁸, —C(O)OR⁸, —C(O)NR⁸R⁹,—HC═NR⁸, —CN, —OR⁸, —OC(O)R⁸, —S(O)_(t)—R⁸, NR⁸R⁹, —NR⁸C(O)R⁹, —NO₂,—N═CR⁸R⁹ or halogen; L is hydrogen, substituted or unsubstituted alkyl,substituted or unsubstituted cycloalkyl, substituted or unsubstitutedalkenyl, substituted or unsubstituted aryl, substituted or unsubstitutedheterocyclyl, —COR⁸, —C(O)OR⁸, —C(O)NR⁸R⁹, —HC═NR⁸, —CN, —OR⁸, —OC(O)R⁸,—S(O)_(t)—R⁸, —NR⁸R⁹, —NR⁸C(O)R⁹, or —N═CR⁸R⁹; and wherein the pair R⁴and R^(4B) or the pair R⁵ and R^(5B) taken together may form a carbonylgroup, t is 1, 2 or 3; R⁸ and R⁹ are each independently selected fromhydrogen, substituted or unsubstituted alkyl, substituted orunsubstituted cycloalkyl, substituted or unsubstituted alkenyl,substituted or unsubstituted aryl, substituted or unsubstitutedheterocyclyl, substituted or unsubstituted alkoxy, substituted orunsubstituted aryloxy, halogen; n is 2, 3, 4 or 5; or a pharmaceuticallyacceptable salt, isomer, prodrug or solvate thereof and apharmaceutically acceptable carrier, adjuvant or vehicle.
 2. The methodaccording to claim 1, wherein n is 3 or
 4. 3. The method according toclaim 1, wherein W is an aromatic group selected from substituted orunsubstituted aryl, substituted or unsubstituted heterocyclyl, orsubstituted or unsubstituted phenyl.
 4. The method according to claim 3,wherein W is selected from alkyl, alkoxy and/or halo substituted phenyl.5. The method according to claim 1, wherein R⁵, R^(5B), R⁶ and R⁷ are H.6. The method according to claim 1, wherein R¹, R⁴, R^(4B), R⁵ andR^(5B) are H or in that R¹, R⁵ and R^(5B) are H and R⁴ and R^(4B) takentogether form a carbonyl group.
 7. The method according to claim 5,wherein R² and R³ are alkoxy, or R² is alkoxy and R³ is H.
 8. The methodaccording to claim 6, wherein R² and R³ are alkoxy, or R² is alkoxy andR³ is H.
 9. The method according to any of claims 1-8, wherein thedisease is sleep disorder, shift worker syndrome, jet lag, depression,seasonal affective disorder, migraine, anxiety, psychosis,schizophrenia, pain, cognition and memory disorders, neuronaldegeneration resulting from ischemic events, cardiovascular diseases,hypertension, irritable bowel syndrome, inflammatory bowel disease,spastic colon or urinary incontinence.
 10. The method according to anyof claims 1-8, wherein the disease is a central nervous disorder.